MY192605A - Compositions and methods for inhibiting arginase activity - Google Patents

Compositions and methods for inhibiting arginase activity

Info

Publication number
MY192605A
MY192605A MYPI2017704875A MYPI2017704875A MY192605A MY 192605 A MY192605 A MY 192605A MY PI2017704875 A MYPI2017704875 A MY PI2017704875A MY PI2017704875 A MYPI2017704875 A MY PI2017704875A MY 192605 A MY192605 A MY 192605A
Authority
MY
Malaysia
Prior art keywords
methods
compositions
arginase activity
inhibiting arginase
inhibiting
Prior art date
Application number
MYPI2017704875A
Other languages
English (en)
Inventor
Matthew I Gross
Susanne M Steggerda
Weiqun Li
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of MY192605A publication Critical patent/MY192605A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2017704875A 2015-06-23 2016-06-23 Compositions and methods for inhibiting arginase activity MY192605A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562183524P 2015-06-23 2015-06-23
PCT/US2016/038983 WO2016210106A1 (en) 2015-06-23 2016-06-23 Compositions and methods for inhibiting arginase activity

Publications (1)

Publication Number Publication Date
MY192605A true MY192605A (en) 2022-08-29

Family

ID=57585664

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017704875A MY192605A (en) 2015-06-23 2016-06-23 Compositions and methods for inhibiting arginase activity

Country Status (17)

Country Link
US (4) US10143699B2 (enExample)
EP (1) EP3313410A4 (enExample)
JP (2) JP2018520352A (enExample)
KR (1) KR20180021117A (enExample)
CN (1) CN107921051A (enExample)
AU (1) AU2016281620B2 (enExample)
CA (1) CA2990192A1 (enExample)
EA (1) EA201890113A1 (enExample)
IL (1) IL256352A (enExample)
MA (1) MA42269A (enExample)
MX (1) MX385315B (enExample)
MY (1) MY192605A (enExample)
PH (1) PH12017502391A1 (enExample)
SG (1) SG10202110144TA (enExample)
UA (1) UA123700C2 (enExample)
WO (1) WO2016210106A1 (enExample)
ZA (1) ZA201800328B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104876955B (zh) 2010-04-22 2018-11-23 马尔斯公司 精氨酸酶抑制剂及其治疗应用
WO2012058065A1 (en) 2010-10-26 2012-05-03 Mars Incorporated Boronates as arginase inhibitors
CN107921051A (zh) 2015-06-23 2018-04-17 卡里塞拉生物科学股份公司 抑制精氨酸酶活性的组合物和方法
KR20220118559A (ko) 2015-10-30 2022-08-25 칼리테라 바이오사이언시즈, 인코포레이티드 아르기닌 활성 억제용 조성물 및 방법
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
AU2017382405B2 (en) 2016-12-22 2021-12-16 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108794517B (zh) * 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
CN110709383A (zh) 2017-05-12 2020-01-17 卡里塞拉生物科学股份公司 (3r,4s)-3-乙酰胺基-4-烯丙基-n-(叔丁基)吡咯烷-3-羧酰胺的制备方法
WO2019000163A1 (zh) * 2017-06-26 2019-01-03 余祖江 精氨酸在制备抗肿瘤药物中的用途
CN111491937A (zh) * 2017-12-22 2020-08-04 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的杂环化合物
KR102657919B1 (ko) * 2018-02-17 2024-04-15 아스트라제네카 아베 아르기나제 저해제 및 이의 사용 방법
UA127897C2 (uk) * 2018-03-05 2024-02-07 Аркус Байосайєнсіз, Інк. Інгібітори аргінази
US10851099B2 (en) 2018-03-29 2020-12-01 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
CN111770756B (zh) * 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
EA202190532A1 (ru) * 2018-08-22 2021-07-08 Астразенека Аб Ингибиторы аргиназы и способы их применения
TWI828800B (zh) * 2018-11-16 2024-01-11 美商阿克思生物科學有限公司 Arg1及/或arg2之抑制劑
US20220017541A1 (en) * 2018-11-21 2022-01-20 Black Belt Tx Ltd Inhibitors of arginase
WO2020160707A1 (en) * 2019-02-06 2020-08-13 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
SG11202108503PA (en) * 2019-02-08 2021-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US10967020B2 (en) * 2019-04-05 2021-04-06 King Saud University Method of synthesizing custard apple peel nanoparticles
CN112110944B (zh) * 2019-06-21 2022-02-11 南京谷睿生物科技有限公司 一种化合物及其制备方法和应用
AU2020319132B2 (en) * 2019-07-23 2023-09-07 Astrazeneca Ab Arginase inhibitors and methods of use thereof
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US20250099408A1 (en) 2022-01-21 2025-03-27 Sammy Oyoo OPIYO Improved suramin methods and compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
ATE250923T1 (de) 1997-07-29 2003-10-15 Alcon Lab Inc Galaktomannanpolymere und borat enthaltende augenarzneimittel
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
EP1051167A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
AU2001275870A1 (en) * 2000-07-06 2002-01-21 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
CA2534484A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
EP2172655B1 (en) 2007-07-12 2018-10-24 Sanyo Denki Co., Ltd. Dual reversal-rotating type axial blower
JP2012515799A (ja) 2009-01-26 2012-07-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア アルギナーゼ阻害剤および使用方法
CN104876955B (zh) 2010-04-22 2018-11-23 马尔斯公司 精氨酸酶抑制剂及其治疗应用
WO2012058065A1 (en) 2010-10-26 2012-05-03 Mars Incorporated Boronates as arginase inhibitors
US8894970B2 (en) 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
EP2768491B1 (en) 2011-10-19 2016-12-21 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
CN104540836B (zh) * 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物
EA201690746A1 (ru) 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
EP3270907A1 (en) 2015-03-20 2018-01-24 Sammy Oyoo OPIYO Use of suramin and arginase inhibitors in malignant neoplasia
CN107921051A (zh) 2015-06-23 2018-04-17 卡里塞拉生物科学股份公司 抑制精氨酸酶活性的组合物和方法

Also Published As

Publication number Publication date
US20190343852A1 (en) 2019-11-14
US20210077510A1 (en) 2021-03-18
CN107921051A (zh) 2018-04-17
US10905701B2 (en) 2021-02-02
UA123700C2 (uk) 2021-05-19
MX385315B (es) 2025-03-14
AU2016281620A1 (en) 2018-02-15
MA42269A (fr) 2018-05-02
MX2017016868A (es) 2018-09-06
EP3313410A1 (en) 2018-05-02
EP3313410A4 (en) 2019-01-02
EA201890113A1 (ru) 2018-07-31
US20160375044A1 (en) 2016-12-29
IL256352A (en) 2018-02-28
PH12017502391A1 (en) 2018-06-25
JP2018520352A (ja) 2018-07-26
US10143699B2 (en) 2018-12-04
ZA201800328B (en) 2018-12-19
US20180360860A1 (en) 2018-12-20
US10398714B2 (en) 2019-09-03
WO2016210106A1 (en) 2016-12-29
AU2016281620B2 (en) 2021-07-22
CA2990192A1 (en) 2016-12-29
KR20180021117A (ko) 2018-02-28
SG10202110144TA (en) 2021-10-28
JP2021185146A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
PH12017502391A1 (en) Compositions and methods for inhibiting arginase activity
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MY201783A (en) Compositions and methods for inhibiting arginase activity
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
PH12017501155A1 (en) Thieno [2,3-c] pyrrol-4-one derivatives as erk inhibitors
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MY193968A (en) Use of plinabulin in combination with immune checkpoint inhibitors
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2021006326A (es) Inhibidores de pcna.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX394452B (es) Inhibicion de la actividad de olig2.
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
ZA201901367B (en) Inhibition of olig2 activity
PH12016501838A1 (en) Compounds and their methods of use
HK1248581A1 (en) Compositions and methods for inhibiting arginase activity
WO2015057737A3 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VprBP-RELATED CANCERS
EA202191495A1 (ru) Композиции и способы ингибирования активности аргиназы
GB2546703A (en) Compounds